# Fibrox

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/fibrox

- Industry: Biotechnology
- Headquarters: Shanghai, China
- Latest round: Angel (Jul 12, 2024)
- Investors on record: 3

## About

Established in 2021 and based in Shanghai, China, FibroX operates as a biotechnology company dedicated to providing innovative cell therapy products for intervertebral disc. The CEO of the company, Ming Fan has experience in marketing and product development in the orthopaedic industry. In July 2024, the company closed angel funding co-led by new investors Shanghai Kinetic Medical Co., Ltd. and Yongkan Investment. In June 2025, Fibrox closed a venture funding from new investor Lake Ventures.

The company mainly provides cell therapy products and solutions for patients with degenerative disc disease (DDD). The DDD includes cervical spondylosis, intervertebral disc herniation, lumbar spinal stenosis and other diseases. Its core product is FibroCell human fibroblast injection, which is targeted at patients with early and mid-stage intervertebral disc degeneration. FibroCell human fibroblast injection has completed IIT clinical studies in multiple dose groups. FibroX also provides FibroCellTM allogeneic fibroblast injection, which is a fibroblast therapy for the treatment of intervertebral disc degeneration.

The company generates revenue by providing cell therapy products and solutions for patients with degenerative disc disease, such as FibroCell human fibroblast injection and FibroCellTM allogeneic fibroblast injection.

The company plans to obtain IND approval in late 2025 and uses the angel funding to develop cell therapy products for lumbar disc degeneration.

## Funding rounds

- Angel, Jul 12, 2024 — HY Capital, Yongkan Investment, Shanghai Kinetic Medical Co., Ltd.

## Investors

- HY Capital (https://capitalatlas.ai/funds/hy-capital) — Angel
- Yongkan Investment (https://capitalatlas.ai/funds/yongkan-investment) — Angel
- Shanghai Kinetic Medical Co., Ltd. — Angel